Monday, March 2, 2026

Revive Appoints Infectious Disease Expert As Scientific Adviser

Revive Therapeutics (CSE: RVV) this morning announced that they have appointed Dr David Boulware as scientific advisor, aimed at assisting the company with its previously announced work on infectious diseases.

Boulware is expected to guide Revive on its current and future clinical programs, which includes the research and development strategy for infectious diseases. Boulware is an infectious disease physician-scientist, and is notably the principal investigator of a COVID-19 clinical trial that is looking at hydroxychloroquine and its post-exposure effects on coronavirus (ClinicalTrials.gov Identifier: NCT04308668).

Currently Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota, Boulware is primarily focused on meningitis, with his latest research involving improving the clinical outcomes of HIV-infected persons with cryptococcal meningitis and TB meningitis. Currently, Boulware serves on the United Nations and World Health Organization’s health panels for cryptococcal meningitis, as well as the WHO’s panel for advanced HIV disease.

I am excited to assist Revive in their objective in pursuing the clinical development of Bucillamine for infectious diseases and its prospect as a potential solution for COVID-19.

Dr. David Boulware, MD, MPH, CTropMed, FIDSA

Revive Therapeutics previously announced that it is exploring the use of Bucillamine as a potential treatment for infectious diseases, and that is has filed for a provisional patent in the US entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996).

Revive Therapeutics last traded at $0.08 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

This Could Be the Next Multi-Million Ounce Gold Camp | Mike Bennett

Newmont Stock Drops Despite Massive Cash Flow — Here’s Why | Q4 Earnings

Strongest Gold Bull Market in 30 Years — And It’s Global | Michael Dehn

Recommended

Advanced Gold Acquires Nevada Property With Historic Production At 1,611 g/t Silver

Steadright: Atrium Research Initiates Coverage With $0.50 Price Target

Related News

Bank of America Targets Gold Prices to Reach $3000

The Bank of America has increased its 18-month gold target from $2,000 to $3,000 per...

Tuesday, April 21, 2020, 08:57:24 PM

Hyperinflation: Remember, GDP = Money Supply x Velocity

When trying to wrap my head around economics, I like to simplify basic principles down...

Saturday, April 4, 2020, 01:45:58 PM

CloudMD Announces $10M Bought Deal

This evening CloudMD Software & Services Inc. (CSE: DOC) announced a $10M bought deal with...

Tuesday, May 12, 2020, 06:38:02 PM

Havn Life to Supply Revive Therapeutics With Psychedelic Compounds

This morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn...

Tuesday, October 20, 2020, 10:16:16 AM

Steve Bannon is a Socialist: Merge the Fed and Treasury, Start Buying Corporate Debt

Prior to the Stimulus Package passing, an interview that fell under the radar last week...

Saturday, March 28, 2020, 10:27:21 AM